Document:

Exhibit 10.3

 

iSpecimen, Inc.

 

FIRST AMENDED AND RESTATED EXECUTIVE EMPLOYMENT
AGREEMENT

 

This Amended and Restated
Executive Employment Agreement (the “Agreement”) made as of this 24th day of October, 2022, between Benjamin Bielak
(the “Executive”), and iSpecimen, Inc., a Delaware corporation located at 450 Bedford St,
Lexington, MA 02420 (the “Company”).

 

Whereas, the Board of Directors
of the Company believes it to be to its advantage to ensure that the Executive render services as a senior executive officer of the Company
as hereinafter provided;

 

Whereas, the Executive’s
position requires that Executive be trusted with extensive confidential information and trade secrets of the Company and that Executive
develop a thorough and comprehensive knowledge of all details of the Company’s business to improve and extend the business; and

 

Whereas, unless stated herein
otherwise, the parties intend for this Agreement to replace and supersede all other agreements and understandings relating hereto.

 

Now, therefore, for
good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and in consideration of the mutual covenants
herein contained, the parties hereto agree as follows:

 

1.            Title,
Position & Responsibilities. The Executive shall serve as the Chief Information Officer of the Company.
The Executive shall have the powers, duties and responsibilities typically availed to a chief information officer of a similar enterprise,
at a similar stage of commercial development, and with similar financial and operational resources to the Company. The Executive shall
exercise such powers and comply with and perform such directions and duties regarding the business, operations and affairs of the Company
as are consistent with such executive position as may from time to time be vested in or given to Executive by the Board of Directors of
the Company (the “Board”), and consistent with the roles, responsibilities and duties of such an executive position,
and the Executive shall use all commercially reasonable, diligent and faithful efforts to improve, enhance and extend the business of
the Company. The Executive shall at all times report to, and Executive’s activities shall at all times be subject to the direction
and control of the Chief Executive Officer. The Executive agrees to devote substantially all of Executive’s available business time,
attention and services to the discharge of Executive’s duties for the best interests of the Company and its stockholders. The roles,
tasks and responsibilities of the Executive are set forth on Exhibit A.

 

The Executive may engage in outside business and
charitable activities (“Outside Activities”) that do not conflict with Executive’s duties to the Company, or
otherwise impact the Executive’s services to the Company. In order for the Board to determine in good faith whether Executive’s
Outside Activities comply with this paragraph, the Executive shall disclose in advance all Outside Activities to the Company.

 

2.            Compensation:
Salary, Bonuses & Other Benefits. During the term of this Agreement, the Company shall pay the Executive the following
compensation, including the following annual salary, bonuses and other fringe benefits:

 

(A)         Base
Salary. In consideration of the services to be rendered by the Executive to the Company under this Agreement, the Company will
pay to the Executive an annual base salary of $326,000, payable on a bi-weekly basis, and otherwise in conformity with the Company’s
customary practices and policies for the compensation of other senior officers, as such practices shall be established or modified from
time to time (the “Base Salary”).

 

     

    

    

 

The Company and Executive intend for the Base Salary rate described
in Section 2(A) to apply retroactively from June 21, 2022. Accordingly, within 30 days of execution of this Agreement,
the Company shall pay to the Executive a lump sum equal to the difference between the Base Salary and Executive’s annual base salary
immediately prior to the execution of this Agreement, pro-rated for the number of days between June 21, 2022, and the date hereof.

 

Salary payments shall be subject to all
applicable federal and state withholding, payroll and other taxes, in conformity with the Company’s prevailing practices.
Executive’s performance and annual base salary shall be reviewed in January of each calendar year by the compensation
committee of the Board; provided, however, the base salary payable hereunder shall at no time be less than the then
current base salary in effect under this Agreement.

 

(B)         Target
Bonus. Except as stated herein, Executive shall be eligible for a discretionary annual cash bonus (the “Annual Bonus”),
with an individual incentive target of 40% of Executive’s then current Base Salary (the “Target”). The
actual amount of Employee’s Annual Bonus shall be determined, at the reasonable discretion of the Board, on the basis of the Company’s
overall performance during the applicable calendar year and Employee’s achievement of certain measures (the “Annual Bonus
Measures”) during that calendar year, as set forth in Exhibit B. For calendar year 2022 only, Executive’s Annual
Bonus shall be guaranteed at an amount equal to at least 20% of Executive’s then current Base Salary. Any Annual Bonus earned
by Executive for a particular calendar year shall be payable in a lump sum, less required taxes and deductions, on or before March 15
of the following calendar year.

 

(D)         Reimbursement
of Expenses; Fringe Benefits. The Executive will be promptly reimbursed for all of Executive’s business-related travel,
lodging and entertainment expenses in accordance with the Company’s prevailing policy for executive officers. The Executive will
participate on the same basis with all other officers and employees of the Company in the Company’s standard benefits package made
generally available to all other officers and Executives, including 401(k) (if available), group health, long-term and short-term
disability and life insurance programs, and other fringe benefits as may be adopted by the Company from time to time. Nothing herein shall
restrict the Company from modifying or eliminating any Company benefit program, health plan or other fringe benefit at any time.

 

(E)          Equity
Participation. As specific consideration for the non-competition covenants contained in the Restated Restrictive Covenant Agreement
discussed below, the Company will grant a ten (10) year option to purchase 30,000 shares of the Company’s common stock
(with an exercise price equal to the current fair market value of the common stock as determined by the Board on the date of the grant
(the “Option”). Provided the Executive continues to provide the Services to the Company on the applicable vesting date, the
Option shall vest over a four (4) year period, with the first 25% of the shares granted pursuant to the Option vesting on the first
anniversary of the Vesting Commencement Date (as defined below) and the remaining shares granted pursuant to the Option vesting in equal
monthly installments over the following 36 months, such that one hundred percent (100%) of the shares shall be vested on the fourth anniversary
of the Vesting Commencement Date. For purposes of the Option, the “Vesting Commencement Date” shall be June 21, 2022.

 

The Options described in this Section 2(E) shall
be subject to the terms and conditions (including forfeiture terms) contained in Company’s 2021 Equity Incentive Plan (the “Plan”)
and related agreements. The Options shall also be subjected to “double-trigger” accelerated vesting (e.g., in the event
of a Change in Control (as defined in the Plan), 100% of any unvested options shall immediately vest upon Executive’s termination
without “just cause” or resignation for “Good Reason” (as the terms “just cause” and “Good Reason”
are defined below), provided that such termination without “just cause” or resignation for “Good Reason” occurs
within twelve months following such Change in Control. Executive’s ability to vest and exercise the Options, as described above,
shall be contingent on Executive executing grant agreements to be presented to Executive.

 

     

    

    

 

The Board contemplates providing Executive with
additional equity awards based on mutually agreed upon targets. Any such additional awards shall be at the discretion of the Board.

 

In addition, the equity award described in this
Section 2(E) is not intended to disturb any prior equity awards provided to Executive. For the avoidance of doubt, nothing in
this Agreement is intended to disturb the Restricted Stock Unit Agreement entered into by the Company and Executive on June 21, 2021
(the “RSU Agreement”) or the Performance Share Unit Agreement entered into by the Company and Executive on June 21,
2021 (the “PSU Agreement”), and the Company acknowledges that the RSU Agreement and PSU Agreement remain operative, and that
such agreements are incorporated by reference into this Agreement.

 

Executive acknowledges that it is prudent to seek
advice from his tax advisor concerning the tax risks of accepting an award of the Options.

 

(F)          Key
Person Insurance. The Company may maintain, at its option and expense, Key Person Life Insurance (the "Policy")
on the life of Executive for the benefit of the Company with a benefit of $2,000,000. The Executive’s signature to this Agreement
constitutes Executive's written consent to being insured under the Policy. The Executive shall make all necessary applications, submit
to physical examinations and otherwise cooperate with the Company with respect to the purchase of the policy.

 

3.            Performance
Review. In connection with the close of each calendar year, the Board and the Executive shall in good faith review the performance
by, and the compensation payable to, the Executive for the prior year and the proposed performance by, and compensation to, the Executive
for the then forthcoming year. No later than January 31 of each calendar year, the Board and the Executive shall negotiate in good
faith the annual salary and bonus (including targets, performance goals and management objectives), stock-based incentives, and other
forms of incentive compensation for the forthcoming fiscal year. Should the Board fail to engage Executive in this annual salary and bonus
review process, the Executive shall be entitled to a guaranteed Annual Bonus for that calendar year at a rate that is not less than the
Target.

 

4.            Term.
The term of this Agreement shall commence on the date first above written and shall terminate on the earlier to occur of (i) the
death or disability of the Executive, or (ii) the occurrence of any of the circumstances described in Section 5 hereof (the
 “Termination Date”). In the event of death or disability, the Executive or the Executive’s estate, as
applicable, shall receive payment of all unpaid or accrued salary, earned or accrued bonuses, and the vesting of the stock or other equity
participation then held by the Executive, but pro-rated until the date of termination.

 

Notwithstanding the above, Executive shall be,
at all times, an “at-will” employee of the Company. Accordingly, the employment relationship between the Executive and the
Company may be terminated, by either the Company or the Executive, at any time for any reason, subject to the employment termination provisions
set forth in Section 5 below.

 

     

    

    

 

5.            Termination.
 The Executive’s term of employment under this Agreement may be terminated as follows:

 

(A)         At
the Election of the Company for Just Cause. The Company may, immediately and unilaterally, terminate the Executive’s employment
hereunder for just cause at any time during the term of this Agreement, subject in all instances to the terms and conditions of and compliance
with the provisions of this Section 5. Termination of the Executive’s employment by the Company shall constitute a termination
for “just cause” under this Section if such termination is for one or more of the following causes:  (i) the
material failure of Executive to render services to the Company in accordance with Executive’s assigned duties and responsibilities
and consistent with Executive’s title, roles and responsibilities under this Agreement, as reasonably determined by the Board; (ii) intentional
misconduct or gross negligence committed by the Executive in connection with the performance of Executive’s assigned duties or breach
of the material terms of this Agreement or the other agreements executed in connection with this Agreement; (iii) the conviction
of the Executive (or plea of guilty or nolo contendere to) of a felony either in connection with the performance of Executive’s
duties and responsibilities to the Company, or which adversely affects the Executive's ability to perform such duties and responsibilities,
or which otherwise adversely affects the business activities, reputation, goodwill or image of the Company; (iv) the commission by
Executive of an act of fraud, embezzlement, or the deliberate disregard of the material policies or practices of the Company (including
but not limited to employment discrimination or harassment), which results in loss, damage or injury to the Company, or otherwise adversely
affects the business activities, reputation, goodwill or image of the Company; (v) the unauthorized disclosure by Executive of any
trade secret or confidential information of the Company or any of its clients or customers, which results in damage or injury to the Company,
or otherwise adversely affects the business activities, reputation, goodwill or image of the Company or its clients or customers; (vi) the
willful commission by Executive of an act which constitutes unfair competition with the Company; (vii) the use of illegal drugs or
controlled substances that materially interferes with the performance by Executive of the duties or obligations delegated to Executive
as a senior executive of the Company, or which results in damage or injury to the Company, or otherwise adversely affects the business
activities, reputation, goodwill or image of the Company or its customers; (viii) the material failure by the Executive to cooperate
in good faith with a governmental or internal investigation of the Company or its directors, officers or employees, if the Company has
requested the Executive’s cooperation; or (ix) the repeated or continued absence from the performance of work during normal
business hours for reasons other than permitted absence pursuant to applicable law. Furthermore, in all instance under subsections (i),
(ii), (viii) and (ix) hereinabove, the Company may not terminate Executive without first providing Executive with written notice
of the basis for exercising its rights to terminate for just cause, and an opportunity of not less than thirty (30) days
for the Executive to substantially cure such grounds for termination to the Board’s reasonable satisfaction.

 

In the event of any such termination
for just cause above, the Executive shall be entitled to (i) earned but unpaid salary and earned but unpaid bonus through the termination
date, (ii) COBRA benefits, provided Executive makes the appropriate voluntary contribution payments, and subject to applicable law
and the then-prevailing requirements of the Company’s health and insurance plans then in effect, and (iii) no other severance
or other compensation benefits, other than payments which are required by law to be provided to all terminated employees.

 

(B)          Voluntary
Termination. The Executive may voluntarily terminate Executive’s employment at any time during the term of this Agreement
by providing the Company with thirty (30) days prior notice of termination. In the event of any such voluntary termination, the Executive
shall be entitled to (i) earned but unpaid salary and bonuses (including any earned Annual Bonus that remains unpaid as of the date
of termination), (ii) COBRA benefits for the applicable statutory period, with Executive being responsible for the full premium amount
for such COBRA coverage, provided Executive makes the appropriate voluntary premium contribution payments, and subject to applicable law
and the then-prevailing requirements of the Company’s health and insurance plans then in effect, and (iii) no other severance
or other compensation benefits, other than payments which are required by law to be provided to all terminated employees.

 

     

    

    

 

(C)          At
the Election of the Company for Reasons Other Than Just Cause. The Company may terminate the Executive’s employment hereunder
at any time during the term of this Agreement “without cause” by giving not less than thirty (30) days’ prior written
notice to the Executive of the Company’s election to terminate. During such notice period, the Executive will be available on a
full-time basis for the benefit of the Company to assist the Company in matters relating to a transition of the Executive’s duties
and responsibilities. In the event the Company exercises its right to terminate the Executive under this Section, the Company agrees to
pay the Executive (i) salary continuation payments for the period of twelve (12) months (the “Salary Continuation Period”),
at the Executive’s then current base salary rate, (ii) Annual Bonus earned but unpaid as of the termination date, (iii) a
pro-rated Annual Bonus at Target based on the number of days Executive was employed in the year of termination and (iv) COBRA benefits
for the Salary Continuation Period, with the Company providing Executive with continuation coverage upon the same terms and conditions
as if Executive were still an active employee of the Company. Such salary continuation payments shall be payable on a bi-weekly basis
for the duration of the Salary Continuation Period and shall be subject to all applicable taxes.

 

Notwithstanding anything herein to the contrary,
Executive shall not be entitled to receive any payments pursuant to this Section unless Executive has executed and delivered to the
Company a general release with customary, industry-standard terms and conditions, an enforceable non-compete consistent in scope with
the non-compete restrictions contained in Exhibit C hereto, in favor of the Company in form and substance satisfactory to the Company
(and such release is in full force and effect and has not been revoked), which release shall be in full force and effect (and no longer
subject to revocation) within sixty (60) calendar days after Executive’s separation from employment with the Company. In the event
said sixty (60) day period spans more than one calendar year, any payments made pursuant to this Section 5(C) shall not commence
until the later calendar year.

 

(D)          Termination
by Executive for Good Reason. The Executive may also resign Executive’s employment with the Company at any time for any
reason, including Good Reason. In the case of a resignation without Good Reason, the Executive shall provide written notice to the Board
at least thirty (30) days prior to the date of termination. During any notice period provided by the Executive in connection with Executive’s
resignation, the Company may, in its discretion, direct the Executive not to perform any work or report to the office for part or all
of the notice period, although the Executive’s Base Salary and benefits shall continue during such notice period regardless. “Good
Reason” means any one of the following events: (A) a material diminution in the Executive’s duties and responsibilities,
or a change in the Executive’s position within the Company which constitutes a demotion, without the Executive’s prior consent;
(B) a reduction in the Executive’s Base Salary or Target Bonus below the amounts then in effect pursuant to this Agreement
, except in circumstances when the Executive’s Base Salary or Target Bonus are reduced in connection with a pay reduction plan generally
applicable to the Company’s management and employees; or (C) a change in the principal workplace of the Executive to a location
outside of an 35-mile radius from Lexington, Massachusetts; provided, however, that none of the foregoing events shall constitute
Good Reason unless and until the Executive provides the Board with at least thirty (30) days’ prior written notice of Executive’s
intent to resign for Good Reason (which notice is provided not later than thirty (30) days following the date upon which the Executive
receives notice of the event constituting Good Reason), and the Company has not remedied the event allegedly constituting Good Reason
within such 45 day period.

 

     

    

    

 

In the event of any termination for Good Reason,
the Executive shall be entitled to (i) salary continuation payments for the aforementioned Salary Continuation Period, at the Executive’s
then current base salary rate, (ii) any Annual Bonus earned but unpaid as of the termination date, (iii) a pro-rated Annual
Bonus at Target based on the number of days Executive was employed in the year of termination and (iv) COBRA benefits for the Salary
Continuation Period, with the Company providing Executive with continuation coverage upon the same terms and conditions as if Executive
were still an active employee of the Company. Such salary continuation payments shall be payable on a bi-weekly basis for the duration
of the Salary Continuation Period and shall be subject to all applicable taxes.

 

Notwithstanding anything herein to the contrary,
Executive shall not be entitled to receive any payments pursuant to this Section unless Executive has executed and delivered to the
Company a general release with customary, industry-standard terms and conditions, that includes an enforceable non-compete consistent
in scope with the non-compete restrictions contained in Exhibit C hereto, in favor of the Company in form and substance satisfactory
to the Company (and such release is in full force and effect and has not been revoked), which release shall be in full force and effect
(and no longer subject to revocation) within sixty (60) calendar days after Executive’s separation from employment with the Company.
In the event said sixty (60) day period spans more than one calendar year, any payments made pursuant to this Section 5(D) shall
not commence until the later calendar year.

 

6.            280G.
If all, or any portion, of the payments or benefits provided under this Agreement, either alone or together with any other payment or
benefit which you receive or are entitled to receive from the Company or an affiliate, would constitute an “excess parachute payment”
within the meaning of Section 280G of the Code, then, notwithstanding anything in this Agreement or any other agreement or plan to
the contrary, you shall be entitled to receive: (A) the amount of such payments or benefits, reduced such that no portion thereof
shall fail to be tax deductible under Section 280G of the Code (the “Limited Amount”), or (B) if the amounts otherwise
payable hereunder and under any other agreement or plan of the Company or its subsidiaries (without regard to clause (A)), reduced by
all taxes applicable thereto (including, for the avoidance of doubt, the excise tax imposed by Section 4999 of the Code), would be
greater than the Limited Amount reduced by all taxes applicable thereto, the amounts otherwise payable hereunder. All determinations under
this Section 6 shall be made by an accounting, consulting or valuation firm selected, and paid for, by the Company.

 

7.            Noncompetition,
Nonsolicitation, Confidentiality and Inventions Agreement. In connection with Executive’s employment by the Company pursuant
to the terms of this Agreement, and in consideration for the Equity Award provided in paragraph 2(E) of this Agreement, the Executive
shall reconfirm the Company’s standard form of Noncompetition, Nonsolicitation, Confidentiality and Invention Assignment Agreement
(the “Restated Restrictive Covenant Agreement”) attached as Exhibit C. Such Restated Restrictive Covenant
Agreement is an essential part of the subject matter of this Agreement and is incorporated by reference. The Executive hereby confirms,
acknowledges the terms of the Restated Restrictive Covenant Agreement, and hereby agrees to the restrictive covenants set forth therein.
Any breach by the Executive of the material covenants of the Restated Restrictive Covenant Agreement shall be deemed a material breach
by the Executive of this Agreement.

 

8.            Governing
Law; Injunctive Relief. This Agreement and the Restrictive Covenant Agreement shall be governed by and construed in accordance
with the internal laws of the Commonwealth of Massachusetts and shall be deemed to be performable in such state. The Executive acknowledges
that the breach or threatened breach of any of the provisions of this Agreement or the Restrictive Covenant Agreement would give rise
to irreparable injury to either party, which injury would be inadequately compensable in money damages. Accordingly, in the event of any
breach, either party may seek and obtain a restraining order and/or injunction prohibiting the breach or threatened breach of any provision,
requirement or covenant of this Agreement or the Restrictive Covenant Agreement, in addition to and not in limitation of any other legal
remedies which may be available, and without the necessity of posting a bond or other surety.

 

     

    

    

 

9.            Severability.
In case any one or more of the provisions contained in this Agreement or the Restrictive Covenant Agreement for any reason shall be held
to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provision
of this Agreement or the Restrictive Covenant Agreement. In such event this Agreement or the Restrictive Covenant Agreement, as the case
may be, shall be construed, revised, modified and reformed to the maximum extent possible to give effect to the purposes set forth herein
and in the Restrictive Covenant Agreement.

 

10.          Waivers
and Modifications. This Agreement may be modified, and the rights and remedies of any provision hereof may be waived, only in
accordance with this Section. No modification or waiver by the Company shall be effective without the consent of the Executive. No waiver
by either party of any breach by the other party of any provision hereof shall be deemed to be a waiver of any later or other breach thereof
or as a waiver of any other provision of this Agreement. This Agreement and the Restrictive Covenant Agreement set forth all of the terms
of the understandings between the parties with reference to the subject matter set forth herein and may not be waived, changed, discharged
or terminated orally or by any course of dealing between the parties, but only by an instrument in writing signed by the party against
whom any waiver, change, discharge or termination is sought.

 

11.          Assignment.
The Executive acknowledges that the services to be rendered by Executive are unique and personal in nature. Accordingly, the Executive
may not assign any of Executive’s rights or delegate any of Executive’s duties or obligations under this Agreement. The rights
and obligations of the Company under this Agreement shall inure to the benefit of, and shall be binding upon, the successors and assigns
of the Company, including any successor to the Company’s capital stock or assets by reason of a change in control, merger or other
acquisition of the Company.

 

     

    

    

 

12.          Arbitration.
Any controversy, dispute, claim or breach arising out of or relating to this Agreement, including claims for injunctive relief, shall
be submitted to and resolved by arbitration under the General Commercial Rules of the American Arbitration Association (“AAA”).
The Arbitrator shall be appointed by the AAA in accordance with the processes for such appointment established by the AAA. However, the
Arbitrator shall be a licensed attorney with not less than fifteen years practice experience. The decision of such Arbitrator shall be
final and binding on the parties. Such arbitration shall be held in Boston, Massachusetts, and the judgment upon the award rendered shall
be entered by consent in any court having jurisdiction. The Arbitrator shall have the right but not the obligation to assess attorneys’
fees, costs and expenses associated with the arbitration, in the Arbitrator’s sole discretion. In the event of any conflict between
the arbitration rules in effect from time to time and the provisions of this Agreement, the provisions of this Agreement shall prevail
and be controlling. The Arbitrator shall be required to (i) materially follow the substantive rules of applicable law, (ii) accompany
the award with findings of fact and a statement of reasons for the decision. The Arbitrator shall have the authority to permit discovery
for no more than sixty days, to the extent deemed appropriate by the Arbitrator, upon reasonable request of a party. One fact witness
deposition shall be allowed by each of the Company and the Executive, for one full day; any other depositions shall be allowed only with
approval of the Arbitrator. The Arbitrator shall have no power or authority to address or resolve any issue not submitted by the parties.
The Arbitrator shall have the power to grant emergency and injunctive relief as provided in the AAA rules (without the necessity
of a party posting a bond) in the event a party has violated the terms of this Agreement or the Restrictive Covenant Agreement, but no
authority to award punitive and/or exemplary damages. The matter shall be heard within one hundred fifty (150) days of the filing of the
demand and the award issued within fourteen (14) days of the closing of the hearing. Notwithstanding the foregoing, at any time prior
to the commencement of an arbitration proceeding, a party may resort to the courts of the Commonwealth of Massachusetts to seek injunctive
relief only; the parties’ consent to the jurisdiction and venue in the Massachusetts court of competent subject matter jurisdiction
in Suffolk County, Massachusetts, for the purpose of pursuing injunctive relief prior to the filing by any party of an arbitration demand.

 

{Signature Page on Following Page}

 

     

    

    

 

iSpecimen, Inc.

 

EXECUTIVE EMPLOYMENT AGREEMENT

 

IN WITNESS WHEREOF, the
parties hereto have executed, as an instrument under seal, this First Amended and Restated Executive Employment Agreement as of the date
first above written.

 

	iSpecimen, Inc.	 
	 	 
	By: 	/s/ Steven Gullans                                       	 
	 	 
	Title: 	Board Director	 

 

 

Executive: BENJAMIN BIELAK

 

	/s/
    Benjamin Bielak	 
	Signature of Executive	 
	 	 
	69 Robin Hill Road	 
	Street	 
	 	 
	Holliston	MA	01746	 
	City 	State 	ZipExhibit 10.4

 

iSpecimen, Inc.

 

FIRST RESTATED NONCOMPETITION, NONSOLICITATION,
NONDISCLOSURE AND INVENTIONS AGREEMENT

 

The undersigned, BENJAMIN
BIELAK, in consideration for and as a condition of employment as a senior executive officer (the “Executive”) of
iSpecimen, Inc. (the “Company”), or for receiving stock or options, or any other form of compensation,
salary, bonus, benefit or fringe benefits from or in the Company, and in connection with executing an Employment Agreement with the Company,
hereby agrees with the Company as follows:

 

1.            Noncompetition
Covenant. During the period of service relationship with the Company and for the one (1) year period following the termination
of such service relationship for “just cause” (as defined in the Executive’s Employment Agreement) or by reason of Executive’s
resignation from service, Executive will not, as an officer, director, employee, consultant, owner, partner, or in any other capacity,
either directly or through others, except on behalf of the Company, compete with the Company’s Business, as it is constituted on
the date of termination of Executive’s relationship with the Company, in the geographic areas where the Executive provided services
to the geographic areas in which the employee provided services or had a material presence or influence during the two (2) year period
preceding the end of such Executive’s employment, without the Company’s prior written consent. The parties agree that nature
and scope of Executive’s service relationship to the Company requires that the Executive have a material presence and influence
in all geographic locations in which the Company conducts business activities and markets its good and services, including, but not limited
to, the entirety of the United States. Accordingly, the parties acknowledge that the geographic scope of the non-competition restrictions
set forth in this section 1 includes, at least, the entire United States.

 

For purpose of this Section 1, the “Company’s
Business” shall mean: the development, sales, marketing, distribution and commercial exploitation of products or services, including
software and web-based applications and products that link electronic medical records and clinical laboratory specimens (the “Proprietary
Technology”), for the collection of biospecimens from hospitals, clinical laboratories, and similar institutions (the “Partners”)
primarily for distribution and sale to research organizations, academic institutions, government facilities, biopharmaceutical, and diagnostic
companies and similar organizations and entities (the “Customers”).

 

The restrictions set forth in this Section 1
shall not take effect until ten (10) business days after the Effective Date of this Agreement (the “Noncompete Effective Date”).
Executive acknowledges and agrees that the Company provided Executive with notice of the restrictions set forth in this Section 1
at least ten (10) business days before the Noncompete Effective Date.

 

Executive also acknowledges that Executive has
been informed, pursuant to Mass. Gen. L. c. 149, § 24L (the “Act”), that Executive has the right to consult with an attorney
before signing this Agreement.

 

In exchange for the promises contained in this
Section 1: the Company, subject to the approval of its Board of Directors where applicable, shall grant the Executive the Equity
Award described in paragraph 2(E) of the Executive Employment Agreement (the “Consideration Payment”), which the parties
hereto agree is “mutually-agreed upon consideration” as defined in the Act.

 

2.            Non-solicitation
Covenant. During the period of service relationship with the Company and for the one (1) year period following the termination
of such service relationship (for any reason) (the “Restricted Period”), the Executive will not directly or indirectly
either for herself or for any other commercial enterprise, solicit, divert or take away or attempt to solicit, divert or take away, any
of the Company’s Customers, business or prospective Customers in existence at the time of termination of such employment for the
benefit of any enterprise which may be competitive to the Business of the Company, whether directly or indirectly. For purposes of this
Agreement, “prospective Customers” shall include those customers being solicited by the Company at the time of the Executive’s
termination. During such employment with the Company and for a period of one (1) year thereafter, the Executive will not solicit
or discuss with any employee, advisor or consultant of the Company the recruitment, employment or engagement of such Company employee,
advisor or consultant by any enterprise, and whether or not such enterprise is competitive to the Business of the Company, nor recruit,
or attempt to recruit, any such Company employee, advisor or consultant other than on behalf of the Company.

 

     - 1 -

    

    

 

The Executive agrees that for the Restricted Period,
the Executive will not solicit, encourage, or induce, or cause to be solicited, encouraged or induced, directly or indirectly, any Customer,
vendor, supplier or contractor who conducted business with the Company at any time during the one-year period preceding the termination
of the Executive’s relationship with the Company, to terminate or adversely modify any business relationship with the Company or
not to proceed with, or enter into, any business relationship with the Company, nor shall the Executive otherwise interfere with any business
relationship between the Company and any such entity described herein.

 

3.            Nondisclosure
Obligation. The Executive will not at any time, whether during or after the termination of employment, for any reason whatsoever (other
than to promote and advance the Business of the Company), reveal to any person or entity (both commercial and non-commercial) any of the
trade secrets or confidential business information concerning the Company or the trade secrets or confidential business information of
third parties subject to a duty of confidentiality on the part of the Company, including without limitation: development activities; prototypes
and technical specifications; show-how and know-how; marketing plans and strategies; pricing and costing policies; Customer, Partner and
supplier lists and accounts; or nonpublic financial information so far as they have come or may come to the Executive’s knowledge,
except as may be required in the ordinary course of performing her duties as an executive of the Company. This restriction shall not
apply to: (i) information that may be disclosed generally or is in the public domain through no fault of the Executive; (ii) information
received from a third party outside the Company that was disclosed without a breach of any confidentiality obligation; (iii) information
approved for release by written authorization of the Company; or (iv) information that may be required by law or an order of any
court, agency or proceeding to be disclosed. The Executive shall keep secret all matters of such nature entrusted to her and shall not
use or disclose any such information for the benefit of any third party in any manner which may injure or cause loss to the Company, whether
directly or indirectly.

 

4.            Assignment
of Inventions. The Executive expressly understands and agrees that any and all right or interest she obtains in any designs, research,
copyrights, trade secrets, technical specifications, software programs, software and systems documentation, game designs and prototypes,
flowcharts, logic diagrams, software methodologies and algorithms, technical data, know-how and show-how, internal reports and memoranda,
Customer, Partner and vendor lists, marketing plans, pricing policies, inventions, concepts, ideas, expressions, discoveries, improvements
and patent or patent rights which are authored, conceived, devised, developed, reduced to practice, or otherwise obtained by Executive
during the term of this Agreement which relate to or arise out of Executive’s employment with the Company are expressly regarded
as “works for hire” (the “Work Product”). The Executive hereby assigns to the Company the sole and exclusive
right to such Work Product. The Executive agrees that she will promptly disclose to the Company any and all such Work Product, and that,
upon request of the Company, the Executive will execute and deliver any and all documents or instruments and take any other action which
the Company shall deem necessary to assign to and vest completely in the Company, to perfect trademark, copyright and patent protection
with respect to, or to otherwise protect the Company’s trade secrets and proprietary interest in such Work Product. The obligations
of this Section shall continue beyond the termination of the Executive’s employment with respect to such Work Product conceived
of, reduced to practice, or developed by the Executive during the term of this Agreement. The Company agrees to pay any and all copyright,
trademark and patent fees and expenses or other costs incurred by the Executive for any assistance rendered to the Company pursuant to
this Section.

 

     - 2 -

    

    

 

In the event the Company is unable, after reasonable
effort, to secure Executive’s signature on any letters patents, copyright or other analogous protection relating to the Work Product,
whether because of Executive’s physical or mental incapacity or for any other reason whatsoever, Executive hereby irrevocably designates
and appoints the Company and its duly authorized officer and agent as Executive’s agent and attorney-in-fact (which designation
and appointment shall be deemed coupled with an interest and irrevocable and shall survive Executive’s death or incapacity), to
act for and in Executive’s behalf and stead to execute and file any such application or applications and to do all other lawfully
permitted acts to further the prosecution and issuance of letter patent, copyright or other analogous protection thereon with the same
legal force and effect as if executed by Executive. The obligations of this Section shall continue beyond the termination of the
Executive’s employment with the Company with respect to such Work Product conceived of, reduced to practice, or developed by the
Executive during Executive’s tenure with the Company. “Work Product” will not include any business
knowledge, skills and experience of the Executive that would not otherwise constitute a trade secret of the Company under applicable law.
The Executive agrees to keep adequate and current written records of all Work Product made by Executive (solely or jointly with others).
The records will be in form of notes, memoranda, sketches, drawings, and any other format that may be specified by the Company. The records
will be available to and remain the sole property of the Company at all times.

 

5.            Remedies
Upon Breach. The Executive agrees that any breach of this Agreement by the Executive could cause irreparable damage to the Company.
The Company shall have, in addition to any and all remedies of law, the right to an injunction or other equitable relief to prevent any
violation of the Executive’s obligations hereunder, and without the necessity of posting a bond. In the event of any enforcement
of this Agreement, or of any breach, the party who does not prevail shall reimburse the counterparty for such counterparty’s cost
and expenses of enforcement, including attorneys’ fees and expenses. The Executive acknowledges and agrees that the enforcement
of this Agreement is necessary to ensure the preservation, protection and continuity of the confidential business information, trade secrets,
business reputation and goodwill of the Company.

 

6.            Defend
Trade Secrets act Notice. Notwithstanding any provision in this Agreement, the Executive shall not be held criminally or civilly liable
under any federal or state trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a federal,
state, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting
or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding,
provided that such filing is made under seal. Further, an individual who files a lawsuit for retaliation by an employer for reporting
a suspected violation of law may disclose the trade secret to the attorney of the individual and use the trade secret information in the
court proceeding, provided that the individual (A) files any document containing the trade secret under seal, and (B) does not
disclose the trade secret, except pursuant to a court order.

 

7.            Miscellaneous.
The obligations of the Executive under this Agreement shall survive the termination of the Executive’s relationship with the Company
regardless of the manner of such termination. All covenants and agreements hereunder shall inure to the benefit of and be enforceable
by the successors of the Company. This Agreement shall be governed by, and construed in accordance with, the internal laws of the Commonwealth
of Massachusetts, and notwithstanding and excepting its conflicts of laws principles. Any waiver by the Company of a breach of any provision
of this Agreement shall not operate or be construed as a waiver of any subsequent breach hereof. If one or more of the provisions contained
in this Agreement shall for any reason be held to be excessively broad as to scope, activity or subject matter so as to be unenforceable
at law, such provision(s) shall be construed and reformed by the appropriate judicial body by limiting and reducing it (or them),
so as to be enforceable to the maximum extent compatible with the applicable law as it shall then appear. If the Executive violates the
provisions of any of Sections 1-4 inclusive, the Executive shall continue to be bound by the restrictions set forth in such sections until
a period of the later of one (1) year or for the duration that the restrictive period has run its course without any violation of
such provisions. During the term of this Agreement and following any termination, no party shall make or publish any negative or derogatory
remarks concerning the other party (or the case of the Company, any remarks concerning its business, operations, Customers, Partners,
strategic relationships, products and services, software, or its directors, officers, employees, personnel, stockholders, agents or representatives).
The Executive understands that this Agreement does not create an obligation on the part of the Company to continue the Executive’s
employment with the Company, and the Executive acknowledges that he or she is employed “at will.” The Agreement may be executed
and delivered in counterparts, and by digital signature, facsimile signature or other similar evidence of execution, and this Agreement
may be delivered and executed by electronic or facsimile transmission, portable document format, hand delivery, overnight courier service,
first class mail (postage prepaid), or any other commercial means.

 

     - 3 -

    

    

 

8.            Arbitration.
Any controversy, dispute, claim or breach arising out of or relating to this Agreement shall be submitted for settlement to an arbitrator
agreed upon by the parties. The principles of Arbitration set forth in the Executive Employment Agreement shall apply to any controversy,
dispute, claim or breach arising out of or relating to this Agreement.

 

IN WITNESS WHEREOF,
the undersigned Executive and the Company have executed this Restated Noncompetition, Nonsolicitation, Nondisclosure and Inventions Agreement
as of this 24th day of October, 2022.

 

	iSpecimen, Inc.	 	Executive: BENJAMIN
    BIELAK
	 	 	 
	By:	/s/
Steven Gullans           	 	/s/ Benjamin Bielak
	 	 	Signature of Executive
	Title:	Board Director	 	 
	 	 	 
	Dated: October 24, 2022	 	 

 

     - 4 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00349-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00349-of-00352.parquet"}]]